Spyre Therapeutics (SYRE) Return on Equity: 2016-2025
Historic Return on Equity for Spyre Therapeutics (SYRE) over the last 10 years, with Sep 2025 value amounting to -0.33%.
- Spyre Therapeutics' Return on Equity rose 29.00% to -0.33% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.33%, marking a year-over-year increase of 29.00%. This contributed to the annual value of -0.59% for FY2024, which is 230.00% up from last year.
- Spyre Therapeutics' Return on Equity amounted to -0.33% in Q3 2025, which was up 25.79% from -0.44% recorded in Q2 2025.
- Over the past 5 years, Spyre Therapeutics' Return on Equity peaked at 11.04% during Q4 2023, and registered a low of -2.17% during Q1 2024.
- Over the past 3 years, Spyre Therapeutics' median Return on Equity value was -0.44% (recorded in 2025), while the average stood at 0.77%.
- Per our database at Business Quant, Spyre Therapeutics' Return on Equity surged by 1,246bps in 2023 and then slumped by 1,153bps in 2024.
- Quarterly analysis of 5 years shows Spyre Therapeutics' Return on Equity stood at -0.83% in 2021, then slumped by 59bps to -1.42% in 2022, then skyrocketed by 1,246bps to 11.04% in 2023, then tumbled by 1,153bps to -0.49% in 2024, then rose by 29bps to -0.33% in 2025.
- Its Return on Equity stands at -0.33% for Q3 2025, versus -0.44% for Q2 2025 and -0.42% for Q1 2025.